Proteomic analysis of cancer-cell mitochondria

Mitochondrial dysfunction and mutations in mitochondrial DNA have been frequently reported in cancer cells. Mitochondrial gene-expression signatures of transformed cells have been identified; however, the phenotypic effects of these genetic alterations remain to be established. Identification of mitochondrial proteins that are aberrantly expressed in cancer cells has been made possible by the recent development of mitochondrial functional proteomics and could identify new markers for early detection and risk assessment, as well as targets for therapeutic intervention.

[1]  B. G. Sanders,et al.  RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells involves Bax translocation to mitochondria. , 2003, Cancer research.

[2]  René Bernards,et al.  Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB , 2003, Nature.

[3]  Katsuya Yamashita,et al.  Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Mary F. Lopez,et al.  High‐throughput profiling of the mitochondrial proteome using affinity fractionation and automation , 2000, Electrophoresis.

[5]  David Sidransky,et al.  Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.

[6]  J. Califano,et al.  Mitochondrial DNA alterations in thyroid cancer , 2003, Journal of surgical oncology.

[7]  J. Califano,et al.  Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  I. Nishino,et al.  Defects of intergenomic communication: autosomal disorders that cause multiple deletions and depletion of mitochondrial DNA. , 2001, Seminars in cell & developmental biology.

[9]  E Gabrielson,et al.  Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. , 2001, Cancer research.

[10]  J. Jen,et al.  Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. , 2000, Science.

[11]  R. Gilkerson,et al.  Quantitative proteomics: the copy number of pyruvate dehydrogenase is more than 102‐fold lower than that of complex III in human mitochondria , 2002, FEBS Letters.

[12]  Ronald W. Davis,et al.  Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar–coding strategy , 1996, Nature Genetics.

[13]  S. Salvioli,et al.  Early changes in intramitochondrial cardiolipin distribution during apoptosis. , 2002, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[14]  E. Fung,et al.  ProteinChip clinical proteomics: computational challenges and solutions. , 2002, BioTechniques.

[15]  K. Yeh,et al.  Novel heteroplasmic frameshift and missense somatic mitochondrial DNA mutations in oral cancer of betel quid chewers , 2003, Genes, chromosomes & cancer.

[16]  G. Kroemer,et al.  Mitochondrion as a novel target of anticancer chemotherapy. , 2000, Journal of the National Cancer Institute.

[17]  G. Daley,et al.  Novel retroviral vectors to facilitate expression screens in mammalian cells. , 2002, Nucleic acids research.

[18]  Zhongmin Guo,et al.  Electrophile and oxidant damage of mitochondrial DNA leading to rapid evolution of homoplasmic mutations , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Nan Hu,et al.  2D Differential In-gel Electrophoresis for the Identification of Esophageal Scans Cell Cancer-specific Protein Markers* , 2002, Molecular & Cellular Proteomics.

[20]  Mary F. Lopez,et al.  Applied proteomics: mitochondrial proteins and effect on function. , 2002, Circulation research.

[21]  Stephen Barnes,et al.  High throughput two‐dimensional blue‐native electrophoresis: A tool for functional proteomics of mitochondria and signaling complexes , 2002, Proteomics.

[22]  S. Parus,et al.  Three-dimensional protein map according to pI, hydrophobicity and molecular mass. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[23]  R. Iggo,et al.  Induction of an interferon response by RNAi vectors in mammalian cells , 2003, Nature Genetics.

[24]  P. Courchesne,et al.  Two‐dimensional electrophoresis of human placental mitochondria and protein identification by mass spectrometry: Toward a human mitochondrial proteome , 1998, Electrophoresis.

[25]  G. Kroemer,et al.  Mitochondrial control of apoptosis: an overview. , 1999, Biochemical Society symposium.

[26]  Alain Van Dorsselaer,et al.  Proteomic Consequences of a Human Mitochondrial tRNA Mutation beyond the Frame of Mitochondrial Translation* , 2003, Journal of Biological Chemistry.

[27]  S. Nomoto,et al.  Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. , 2001, Cancer research.

[28]  S. Nomoto,et al.  Mitochondrial mutations in early stage prostate cancer and bodily fluids , 2001, Oncogene.

[29]  A. Alonso,et al.  Detection of somatic mutations in the mitochondrial DNA control region of colorectal and gastric tumors by heteroduplex and single‐strand conformation analysis , 1997, Electrophoresis.

[30]  Charis Eng,et al.  A role for mitochondrial enzymes in inherited neoplasia and beyond , 2003, Nature Reviews Cancer.

[31]  I. Scheffler,et al.  Mitochondria make a come back. , 2001, Advanced drug delivery reviews.

[32]  H. Lodish,et al.  Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene. , 1998, Genes & development.

[33]  K. Okawa,et al.  A subset of newly synthesized polypeptides in mitochondria from human endothelial cells exposed to hydroperoxide stress. , 2002, Free radical biology & medicine.

[34]  D. Wallace.  Mitochondrial diseases in man and mouse. , 1999, Science.

[35]  R. Aebersold,et al.  The mitochondrial antioxidant defence system and its response to oxidative stress , 2001, Proteomics.

[36]  Johannes P C Vissers,et al.  A novel Interface for variable flow nanoscale LC/MS/MS for improved proteome coverage , 2002, Journal of the American Society for Mass Spectrometry.

[37]  G Parmigiani,et al.  Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. , 2001, Cancer research.

[38]  N. Anderson,et al.  Proteome and proteomics: New technologies, new concepts, and new words , 1998, Electrophoresis.

[39]  S. Weinberger,et al.  Recent advancements in surface‐enhanced laser desorption/ionization‐time of flight‐mass spectrometry , 2000, Electrophoresis.

[40]  S. Gygi,et al.  Correlation between Protein and mRNA Abundance in Yeast , 1999, Molecular and Cellular Biology.

[41]  J. Seilhamer,et al.  A comparison of selected mRNA and protein abundances in human liver , 1997, Electrophoresis.

[42]  Ronald W. Davis,et al.  Functional profiling of the Saccharomyces cerevisiae genome , 2002, Nature.

[43]  L. Peltonen,et al.  A third locus predisposing to multiple deletions of mtDNA in autosomal dominant progressive external ophthalmoplegia. , 1999, American journal of human genetics.

[44]  William C Copeland,et al.  Mitochondrial DNA Alterations in Cancer , 2002, Cancer investigation.

[45]  S. Kornbluth,et al.  Mitochondria at the Crossroad of Apoptotic Cell Death , 1999, Journal of bioenergetics and biomembranes.

[46]  Robin A. J. Smith,et al.  Specific Modification of Mitochondrial Protein Thiols in Response to Oxidative Stress , 2002, The Journal of Biological Chemistry.

[47]  Emanuel F Petricoin,et al.  Mass spectrometry-based diagnostics: the upcoming revolution in disease detection. , 2003, Clinical chemistry.